Notably, homozygous cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) gene deletions of the chromosome 9p21 have been linked to a significantly shortened time to meningioma progression and has been recommended as diagnostic characteristics by the WHO grading since the last revision of the classification system [20]. Here, CDKN2A is linked to meningioma.